Cargando…
Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
COVID-19, coronavirus disease 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic. At the time of writing this (October 14, 2020), more than 38.4 million people have become affected, and 1.0 million people have died across the world. The death rate...
Autores principales: | Bonam, Srinivasa Reddy, Kotla, Niranjan G., Bohara, Raghvendra A., Rochev, Yury, Webster, Thomas J., Bayry, Jagadeesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834523/ https://www.ncbi.nlm.nih.gov/pubmed/33519949 http://dx.doi.org/10.1016/j.nantod.2020.101051 |
Ejemplares similares
-
Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen presenting cells
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2023) -
Progress and Challenges in the Use of MAP1LC3 as a Legitimate Marker for Measuring Dynamic Autophagy In Vivo
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2020) -
IFN-γ Induces PD-L1 Expression in Primed Human Basophils
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2022) -
THEME: “Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases”
por: Retnakumar, Sruthi Vijaya, et al.
Publicado: (2023) -
Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)